A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects

Documenti analoghi

• The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects
  di: Yue Liu, et al.
  Pubblicazione: (2025)
• Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin‐4‐IgG4‐Fc in healthy subjects: A phase 1, single‐centre, randomized, double‐blind, dose escalation study
  di: Gui‐Ling Chen, et al.
  Pubblicazione: (2024)
• The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist ( BGM0504 ) in healthy volunteers: A dose‐escalation Phase I study
  di: Yuxin Fan, et al.
  Pubblicazione: (2025)
• Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4 , a novel once‐weekly basal insulin, in healthy participants: A randomized trial
  di: Chengyong Tang, et al.
  Pubblicazione: (2025)
• Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial
  di: Yingying Xiang, et al.
  Pubblicazione: (2024)